Overview

Re-examination Study of EMEND (Aprepitant) (MK-0869-184)

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
0
Participant gender:
All
Summary
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation. Its aim is to reconfirm the clinical usefulness of EMEMD (aprepitant) through collecting the safety information according to the Re-examination Regulation for New Drugs.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Aprepitant
Fosaprepitant
Criteria
Inclusion Criteria:

- Participants who are treated with EMEND for the first time as per the EMEND label

Exclusion Criteria:

- Contraindication to EMEND